This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions
Extension: CharacteristicDescription
Official URL: http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description
|
Version:
1.0.0-ballot
|
Standards status:
Draft
|
Maturity Level: 1
|
Computable Name: CharacteristicDescription |
Natural language description of the characteristic.
Context of Use
This extension may be used on the following element(s):
- Element ID Group.characteristic
Usage info
Usage:
- Use this Extension: GroupR6
- Examples for this Extension: COVID_19PneumoniaHospitalizedAdult, CohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years, CohortDefinition_Cardiovascular_event, StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study... Show 54 more, StudyEligibilityCriteria_Obese_patients_18_years_old, Bariatric_Surgery_RYGB_VSG_LAGB_BPD, ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD, ComparatorGroup_Obese_patients_18_years_old_without_bariatric_surgery, StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial, OutcomeDefinition_HbA1c_at_60_months, OutcomeDefinition_HbA1c_at_24_months, OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control, OutcomeDefinition_HbA1c_at_12_months, ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort, ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort, OutcomeDefinition_HbA1c_at_36_months, OutcomeDefinition_Nonfatal_myocardial_infarction_or_stroke, CohortDefinition_Nonfatal_myocardial_infarction, CohortDefinition_Nonfatal_stroke, OutcomeDefinition_New_onset_depression, OutcomeDefinition_Diabetes_in_remission, OutcomeDefinition_HbA1c_at_6_months, MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up, MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, Severely_Obese_Adults_2018_Norwegian_Cohort, CohortDefinition_Severe_obesity, CohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity, CohortDefinition_BMI_criteria_for_ADA_surgery_recommendation, CohortDefinition_Proxy_criteria_for_surgical_candidates, CohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans, CohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, CohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17, CohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration, CohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, CohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery, EvidenceReportSubject_Clinical_Outcomes_for_Effects_of_Bariatric_Surgery, NetEffectContributions_Bariatric_Surgery_Example_for_GIN_2022, SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review, SearchStrategy_PubMed_search_for_Wonder_Woman, SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer, ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort, Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days, ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis, ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin, MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs, EGFR_45_59, CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter, CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges, CohortDefinition_Heart_failure_based_on_Phenotypes, CohortDefinition_At_least_2_risk_factors_for_stroke, Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16, StudyGroup_Bariatric_Surgery_Trial_Enrollment_Group, Group/33395, Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis, StudyGroup_DIBASY_Trial_Enrollment_Group, Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill and Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
Formal Views of Extension Content
Description of Profiles, Differentials, Snapshots, and how the XML and JSON presentations work.
This structure is derived from Extension
Summary
Simple Extension of type markdown: Natural language description of the characteristic.
Maturity: 1
This structure is derived from Extension
Summary
Simple Extension of type markdown: Natural language description of the characteristic.
Maturity: 1
Differential View
This structure is derived from Extension
Other representations of profile: CSV, Excel, Schematron
Constraints
Id | Grade | Path(s) | Details | Requirements |
ele-1 | error | **ALL** elements | All FHIR elements must have a @value or children : hasValue() or (children().count() > id.count()) | |
ext-1 | error | **ALL** extensions | Must have either extensions or value[x], not both : extension.exists() != value.exists() | |